Guardant Health price target lowered to $66 from $73 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Guardant Health to $66 from $73 and keeps an Overweight rating on the shares, arguing there were "no surprises" in the company’s quarterly report following a January pre-announcement. Though the mid-point of guidance was modestly below recently lowered estimates, soft guidance was anticipated and the firm argues that "now isn’t the time to throw in the towel" as it sees a compelling risk/reward given its view of "multiple areas of conservatism" in the outlook and an attractive valuation.